​
​

SAB Biotherapeutics Ownership 2024 | Who Owns SAB Biotherapeutics Now?

OverviewForecastRevenueFinancialsChart

Institutional Ownership

5.11%

Insider Ownership

19.15%

Retail Ownership

75.74%

Institutional Holders

37.00

SAB Biotherapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----951-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----54-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----294-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----44,476-100.00%-Mar 31, 2024
STATE STREET CORP----81,241-100.00%-Mar 31, 2024
VANGUARD GROUP INC----996,132-100.00%-Mar 31, 2024
FMR LLC----343-100.00%-Mar 31, 2024
1ST SOURCE BANK----10,000-100.00%-Mar 31, 2024
FIRST MANHATTAN CO. LLC.----277,777-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----16,238-100.00%-Mar 31, 2024
MORGAN STANLEY----11,506-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----63,100-100.00%-Mar 31, 2024
PEAPACK GLADSTONE FINANCIAL CORP----52,296-100.00%-Mar 31, 2024
BVF INC/IL----9,178,282-100.00%-Mar 31, 2024
SILVER OAK SECURITIES, INCORPORATED----51,891-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----356,364-100.00%-Mar 31, 2024
BLACKROCK INC.----52,643-100.00%-Mar 31, 2024
MARINER, LLC----69,000-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----16,719-100.00%-Mar 31, 2024
RTW INVESTMENTS, LP----9,178,282-100.00%-Mar 31, 2024

SAB Biotherapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----951-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----54-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----294-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----44,476-100.00%-Mar 31, 2024
STATE STREET CORP----81,241-100.00%-Mar 31, 2024
VANGUARD GROUP INC----996,132-100.00%-Mar 31, 2024
FMR LLC----343-100.00%-Mar 31, 2024
1ST SOURCE BANK----10,000-100.00%-Mar 31, 2024
FIRST MANHATTAN CO. LLC.----277,777-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----16,238-100.00%-Mar 31, 2024
MORGAN STANLEY----11,506-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----63,100-100.00%-Mar 31, 2024
PEAPACK GLADSTONE FINANCIAL CORP----52,296-100.00%-Mar 31, 2024
BVF INC/IL----9,178,282-100.00%-Mar 31, 2024
SILVER OAK SECURITIES, INCORPORATED----51,891-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----356,364-100.00%-Mar 31, 2024
BLACKROCK INC.----52,643-100.00%-Mar 31, 2024
MARINER, LLC----69,000-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----16,719-100.00%-Mar 31, 2024
RTW INVESTMENTS, LP----9,178,282-100.00%-Mar 31, 2024

The largest SAB Biotherapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of SAB Biotherapeutics (SABS), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BANK OF AMERICA CORP /DE/----54-100.00%-Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD----69-100.00%-Mar 31, 2024
NEWEDGE ADVISORS, LLC----145-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----294-100.00%-Mar 31, 2024
FMR LLC----343-100.00%-Mar 31, 2024
UBS GROUP AG----500-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----951-100.00%-Mar 31, 2024
GS INVESTMENTS, INC.----2,000-100.00%-Mar 31, 2024
LM ADVISORS LLC----3,620-100.00%-Mar 31, 2024
SPECTRUM WEALTH COUNSEL, LLC----5,030-100.00%-Mar 31, 2024
ELGETHUN CAPITAL MANAGEMENT----5,435-100.00%-Mar 31, 2024
BAIRD FINANCIAL GROUP, INC.----10,000-100.00%-Mar 31, 2024
1ST SOURCE BANK----10,000-100.00%-Mar 31, 2024
MORGAN STANLEY----11,506-100.00%-Mar 31, 2024
NADLER FINANCIAL GROUP, INC.----13,750-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----15,235-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----16,238-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----16,719-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----44,476-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----46,373-100.00%-Mar 31, 2024

As of Mar 31 2024, SAB Biotherapeutics's largest institutional buyer is BANK OF AMERICA CORP /DE/. The company purchased -54.00 stocks of SABS, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BVF INC/IL----9,178,282-100.00%-Mar 31, 2024
RTW INVESTMENTS, LP----9,178,282-100.00%-Mar 31, 2024
SESSA CAPITAL IM, L.P.----4,584,571-100.00%-Mar 31, 2024
VANGUARD GROUP INC----996,132-100.00%-Mar 31, 2024
FIRST PREMIER BANK----807,535-100.00%-Mar 31, 2024
PATHSTONE HOLDINGS, LLC----506,513-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----356,364-100.00%-Mar 31, 2024
FIRST MANHATTAN CO. LLC.----277,777-100.00%-Mar 31, 2024
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC----192,027-100.00%-Mar 31, 2024
KESTRA ADVISORY SERVICES, LLC----88,000-100.00%-Mar 31, 2024
STATE STREET CORP----81,241-100.00%-Mar 31, 2024
MARINER, LLC----69,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----63,100-100.00%-Mar 31, 2024
BLACKROCK INC.----52,643-100.00%-Mar 31, 2024
PEAPACK GLADSTONE FINANCIAL CORP----52,296-100.00%-Mar 31, 2024
SILVER OAK SECURITIES, INCORPORATED----51,891-100.00%-Mar 31, 2024
CREATIVE PLANNING----47,518-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----46,373-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----44,476-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----16,719-100.00%-Mar 31, 2024

As of Mar 31 2024, SAB Biotherapeutics's biggest institutional seller is BVF INC/IL. The company sold -9.18M shares of SABS, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BVF INC/IL----9,178,282-100.00%-Mar 31, 2024
RTW INVESTMENTS, LP----9,178,282-100.00%-Mar 31, 2024
SESSA CAPITAL IM, L.P.----4,584,571-100.00%-Mar 31, 2024
VANGUARD GROUP INC----996,132-100.00%-Mar 31, 2024
FIRST PREMIER BANK----807,535-100.00%-Mar 31, 2024
PATHSTONE HOLDINGS, LLC----506,513-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----356,364-100.00%-Mar 31, 2024
FIRST MANHATTAN CO. LLC.----277,777-100.00%-Mar 31, 2024
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC----192,027-100.00%-Mar 31, 2024
KESTRA ADVISORY SERVICES, LLC----88,000-100.00%-Mar 31, 2024
STATE STREET CORP----81,241-100.00%-Mar 31, 2024
MARINER, LLC----69,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----63,100-100.00%-Mar 31, 2024
BLACKROCK INC.----52,643-100.00%-Mar 31, 2024
PEAPACK GLADSTONE FINANCIAL CORP----52,296-100.00%-Mar 31, 2024
SILVER OAK SECURITIES, INCORPORATED----51,891-100.00%-Mar 31, 2024
CREATIVE PLANNING----47,518-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----46,373-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----44,476-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----16,719-100.00%-Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----16,238-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----15,235-100.00%-Mar 31, 2024
NADLER FINANCIAL GROUP, INC.----13,750-100.00%-Mar 31, 2024
MORGAN STANLEY----11,506-100.00%-Mar 31, 2024
1ST SOURCE BANK----10,000-100.00%-Mar 31, 2024
BAIRD FINANCIAL GROUP, INC.----10,000-100.00%-Mar 31, 2024
ELGETHUN CAPITAL MANAGEMENT----5,435-100.00%-Mar 31, 2024
SPECTRUM WEALTH COUNSEL, LLC----5,030-100.00%-Mar 31, 2024
LM ADVISORS LLC----3,620-100.00%-Mar 31, 2024
GS INVESTMENTS, INC.----2,000-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----951-100.00%-Mar 31, 2024
UBS GROUP AG----500-100.00%-Mar 31, 2024
FMR LLC----343-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----294-100.00%-Mar 31, 2024
NEWEDGE ADVISORS, LLC----145-100.00%-Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD----69-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----54-100.00%-Mar 31, 2024

SAB Biotherapeutics's largest sold out institutional shareholder by shares sold is BVF INC/IL, sold -9.18M shares, valued at -, as of undefined.

SAB Biotherapeutics Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.04%84,000--Mar 28, 2024
ALPS ETF Trust0.00%42,491--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%1,349,462--Mar 31, 2024
ETF Managers Trust0.00%13,581--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%328,656--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%174,128174,128-Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%16,238--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%10,730--Mar 31, 2024
ETF Series Solutions0.00%6,405--Jan 31, 2024
FIDELITY CONCORD STREET TRUST0.00%33,15933,159-Feb 29, 2024
VARIABLE INSURANCE PRODUCTS FUND II0.00%787--Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%1,6231,623-Jan 31, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%1,0731,073-Mar 31, 2024
USAA MUTUAL FUNDS TRUST0.00%3,587--Jan 31, 2024
PROSHARES TRUST0.00%3,619--Feb 29, 2024
EQ ADVISORS TRUST0.00%4,054--Mar 31, 2024
iSHARES TRUST0.00%53,316--Mar 31, 2024
Invesco Exchange-Traded Fund Trust II0.00%803--Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%607--Mar 31, 2024

SAB Biotherapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 84.00K shares, compromising 0.04% of its total assets.

SAB Biotherapeutics Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
31 Dec, 23375.71%
30 Sep, 2335-7.89%
30 Jun, 23382.70%
31 Mar, 23372.78%
31 Dec, 22362.86%
30 Sep, 2235-
30 Jun, 223534.62%
31 Mar, 2226-23.53%
31 Dec, 21343300.00%
30 Sep, 211-

As of 31 Dec 23, 37 institutions are holding SAB Biotherapeutics's shares, representing an increase of 5.71% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Dec, 2326,785,910591.27%
30 Sep, 233,874,859-2.09%
30 Jun, 233,957,7032.29%
31 Mar, 233,868,963-5.44%
31 Dec, 224,091,45923.76%
30 Sep, 223,306,0847.32%
30 Jun, 223,080,45072.25%
31 Mar, 221,788,313-42.24%
31 Dec, 213,096,3375060.56%
30 Sep, 2160,000-

SAB Biotherapeutics (SABS) has 26.79M shares outstanding as of 31 Dec 23, up 591.27% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Dec, 235.11%8.65%
30 Sep, 237.68%12.46%
30 Jun, 237.85%13.32%
31 Mar, 237.68%8.69%
31 Dec, 229.40%15.92%
30 Sep, 227.68%14.97%
30 Jun, 227.16%41.64%
31 Mar, 224.15%8.18%
31 Dec, 217.12%37395.36%
30 Sep, 210.14%-

As of 31 Dec 23, SAB Biotherapeutics is held by 5.11% institutional shareholders, representing a 8.65% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Dec, 231550.00%
30 Sep, 2310-16.67%
30 Jun, 23129.09%
31 Mar, 2311-35.29%
31 Dec, 221721.43%
30 Sep, 2214-33.33%
30 Jun, 222131.25%
31 Mar, 2216-52.94%
31 Dec, 21343300.00%
30 Sep, 211-

15 institutional shareholders have increased their position in SABS stock as of 31 Dec 23 compared to 10 in the previous quarter (a 50.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Dec, 23350.00%
30 Sep, 232-50.00%
30 Jun, 234-42.86%
31 Mar, 237-12.50%
31 Dec, 22833.33%
30 Sep, 226-14.29%
30 Jun, 22716.67%
31 Mar, 226-
31 Dec, 21--
30 Sep, 21--

3 institutional shareholders have reduced their position in SABS stock as of 31 Dec 23 compared to 2 in the previous quarter (a 50.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Dec, 23375.71%26,785,910591.27%5.11%8.65%1550.00%350.00%
30 Sep, 2335-7.89%3,874,859-2.09%7.68%12.46%10-16.67%2-50.00%
30 Jun, 23382.70%3,957,7032.29%7.85%13.32%129.09%4-42.86%
31 Mar, 23372.78%3,868,963-5.44%7.68%8.69%11-35.29%7-12.50%
31 Dec, 22362.86%4,091,45923.76%9.40%15.92%1721.43%833.33%
30 Sep, 2235-3,306,0847.32%7.68%14.97%14-33.33%6-14.29%
30 Jun, 223534.62%3,080,45072.25%7.16%41.64%2131.25%716.67%
31 Mar, 2226-23.53%1,788,313-42.24%4.15%8.18%16-52.94%6-
31 Dec, 21343300.00%3,096,3375060.56%7.12%37395.36%343300.00%--
30 Sep, 211-60,000-0.14%-1---

SAB Biotherapeutics Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 24, 2024Conley Mark Williamofficer See RemarksSell25,000$4.79$119.75K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 13, 2024To Lucyofficer See RemarksA-AwardBuy125,000$2.35$293.75K125,000
Jul 31, 2024To Lucy-Buy----
Jul 17, 2024Spragens Jeffrey Gdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024Polvino William Jamesdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024Polvino William Jamesdirector-A-AwardBuy13,958$2.90$40.48K13,958
Jul 17, 2024SKYLER JAY Sdirector-A-AwardBuy35,000$2.90$101.50K35,000
Jul 17, 2024SKYLER JAY Sdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024Sullivan Eddie Joedirector, officer PRESIDENTA-AwardBuy46,528$5.40$251.25K46,528
Jul 17, 2024Sullivan Eddie Joedirector, officer PRESIDENTA-AwardBuy4,447$2.90$12.90K4,447
Jul 17, 2024Lucera Erickdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024HAMILTON CHRISTINE Edirector-A-AwardBuy44,202$5.40$238.69K44,202
Jul 17, 2024HAMILTON CHRISTINE Edirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024HAMILTON CHRISTINE Edirector-A-AwardBuy5,815$5.40$31.40K5,815
Jul 17, 2024HAMILTON CHRISTINE Edirector-A-AwardBuy4,447$2.90$12.90K4,447
Jul 17, 2024HAMILTON CHRISTINE Edirector-A-AwardBuy2,326$2.90$6.75K2,326
Jul 17, 2024Link David Charlesdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jul 17, 2024Link David Charlesdirector-A-AwardBuy9,305$2.90$26.98K9,305
Jul 17, 2024Reich Samuel Jdirector, officer CEO & EXECUTIVE CHAIRMANA-AwardBuy35,700$2.90$103.53K35,700
Jul 17, 2024Giberson Scottdirector-A-AwardBuy20,000$2.90$58.00K20,000
Jun 24, 2024Conley Mark Williamofficer See RemarksSell25,000$4.79$119.75K-

The last insider sell of SAB Biotherapeutics's stock was made by Conley Mark William on Jun 24 2024, selling 25,000 shares at $4.79 per share (valued at $119.75K).

SAB Biotherapeutics Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 202418--
Q2 2024-1-
Q1 20245--
Q4 20232111190.91%
Q2 20231--
Q1 202371700.00%
Q4 202261600.00%
Q3 20228--
Q2 20223--
Q1 20229--
Q4 202110161683.33%
Q3 20213--
Q1 202131300.00%

18 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by SAB Biotherapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024---
Q2 2024---
Q1 2024---
Q4 20233--
Q2 2023---
Q1 2023---
Q4 2022---
Q3 20222--
Q2 2022---
Q1 2022---
Q4 202141400.00%
Q3 2021---
Q1 20213--

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of SAB Biotherapeutics's stocks.

SAB Biotherapeutics Peer Ownership

TickerCompany
FRTXFresh Tracks Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
PXMDPaxMedica, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
PCSAProcessa Pharmaceuticals, Inc.
THRDThird Harmonic Bio, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
CDIOCardio Diagnostics Holdings, Inc.

SABS Ownership FAQ

SAB Biotherapeutics is owned by institutional shareholders (5.11%), insiders (19.15%), and public (75.74%). The largest institutional shareholder of SAB Biotherapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).

SAB Biotherapeutics's major institutional shareholders are JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and STATE STREET CORP. The top five shareholders own together 0% of the company's share outstanding.

As of Dec 2023, there are 37 institutional shareholders of SAB Biotherapeutics.

JPMORGAN CHASE & CO owns 0 shares of SAB Biotherapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

As of Mar 2024, BANK OF AMERICA CORP /DE/ holds 0 shares of SAB Biotherapeutics (SABS), compromising 0% of the company, valued at $0.

WELLS FARGO & COMPANY/MN is the third largest holder of SAB Biotherapeutics. The company owns 0 of the company's shares outstanding (worth $0).